Gulley JL - Search Results

1

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.

Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J, Gulley JL. Heery CR, et al. Among authors: gulley jl. Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30. Cancer Immunol Res. 2015. PMID: 26130065 Free PMC article. Clinical Trial.

2

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Zhu M, et al. Cancer Res. 2001 May 1;61(9):3725-34. Cancer Res. 2001. PMID: 11325845

3

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2001 May;7(5):1181-91. Clin Cancer Res. 2001. PMID: 11350882 Clinical Trial.

4

The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Cancer Res. 2001 Oct 15;61(20):7568-76. Cancer Res. 2001. PMID: 11606396

5

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

6

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Terasawa H, et al. Clin Cancer Res. 2002 Jan;8(1):41-53. Clin Cancer Res. 2002. PMID: 11801539

7

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

8

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

9

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Behrens RJ, Gulley JL, Dahut WL. Behrens RJ, et al. Among authors: gulley jl. Am J Ther. 2003 May-Jun;10(3):228-32. doi: 10.1097/00045391-200305000-00011. Am J Ther. 2003. PMID: 12756431

10

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.

Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. Arlen PM, et al. Among authors: gulley jl. J Immunol Methods. 2003 Aug;279(1-2):183-92. doi: 10.1016/s0022-1759(03)00185-6. J Immunol Methods. 2003. PMID: 12969559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters